Where mechanism research is actually moving

The lens

Research budgets and publication volume are a decent proxy for where the field thinks the open questions are. This piece is a survey of where the journals are spending their pages this year, not a recommendation about what to take.

Incretin biology

The incretin space remains the dominant area of metabolic peptide research. Dual and triple agonists are no longer novel; they are an arms race. The interesting work is on receptor bias and tissue selectivity, not on net weight loss.

Tissue repair signalling

The literature around tissue-repair peptides is messier than the marketing suggests. Mechanism papers exist, but the human clinical data is still thin. Expect the next two years to either clarify or deflate several headline compounds.

Mitochondrial-targeted peptides

A small but real corner of the literature is on peptides that localise to the mitochondrial inner membrane and modulate respiration. The mechanism work is strong; the translational human data is early.

Senescence and the inflammasome

Senolytic and senomorphic agents are being explored across multiple modalities, including peptide approaches. This is a watch-this-space area, not a "take this now" area.

Why this matters for your protocol

Not because you should be chasing every new pathway. Because the compounds that survive the next five years of research will be the ones in this list, and you want to know what questions they are answering.

Closing

Mechanism research is not a shopping list. It is a map of the open questions. Read it as a map and your protocol decisions will be better for it.